查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1971915

非小细胞肺癌 (NSCLC) 市场分析及预测（至 2035 年）：按类型、产品类型、技术、应用、最终用户、疾病分期、设备、解决方案和流程划分

Non-Small Cell Lung Cancer (NSCLC) Market Analysis and Forecast to 2035: Type, Product, Technology, Application, End User, Stage, Device, Solutions, Process
出版日期: | 出版商: Global Insight Services | 英文 385 Pages | 商品交期: 3-5个工作天内

价格
简介目录

非小细胞肺癌 (NSCLC) 市场预计将从 2024 年的 195 亿美元成长到 2034 年的 616 亿美元，复合年增长率约为 12.2%。 NSCLC 市场涵盖了 NSCLC（最常见的肺癌类型）治疗方案的研发、生产和分销。该市场以创新治疗方法，例如标靶治疗和免疫疗法，旨在改善患者预后。在发病率上升和精准医疗进步的推动下，由于对研究和临床试验的大量投资，该市场正稳步增长。主要趋势包括个人化医疗方法、联合治疗以及整合生物标记以提高治疗效果。

非小细胞肺癌 (NSCLC) 市场正经历强劲成长，主要得益于标靶治疗和免疫疗法的进步。目前，标靶治疗领域表现最佳，主导EGFR 抑制剂和 ALK 抑制剂因其对特定基因突变的疗效而备受青睐。免疫疗法，尤其是 PD-1 和 PD-L1 抑制剂，是表现第二好的领域，反映出它们作为第一线治疗方案的应用日益广泛。联合治疗发展势头强劲，显着提高了疗效并改善了患者预后。儘管化疗领域呈下降趋势，但仍占据重要地位，尤其是与其他治疗方法合併使用时。个人化医疗正成为一项关键趋势，其驱动力来自基因组分析和生物标记识别技术的进步。这一趋势正在推动伴随诊断领域的创新和投资。此外，由于患者偏好和成本效益的考虑，市场正朝着门诊治疗模式转变。持续的研发投入可望创造新的治疗选择，进一步推动市场成长。

市场区隔
类型 腺癌、鳞状细胞癌、大细胞癌
产品 标靶治疗、免疫疗法、化疗和放射线治疗
科技 生物标记检测、基因检测、诊断影像技术、奈米技术
适应症 第一线治疗、第二线治疗、维持治疗、辅助性治疗、新辅助辅助性治疗
最终用户 医院、癌症研究机构、专科诊所、製药公司
阶段 第一阶段、第二阶段、第三阶段、第四阶段
医疗设备 切片检查设备、诊断影像系统、放射治疗设备
解决方案 病患管理、临床试验和药物研发
过程 药物发现、临床开发、监管核准和商业化

市场概况：

非小细胞肺癌 (NSCLC) 市场正经历动态变化，创新定价策略和新型疗法的推出导致市场份额显着波动。新型疗法的出现满足了未被满足的医疗需求，并改善了患者的治疗效果，从而塑造了市场特征。新进业者的竞争性定价正在重塑市场结构，并促进更广泛的医疗服务取得和应用。主要地区的定价趋势各不相同，受到当地法规结构和医疗政策的影响。随着製药公司继续专注于研发以保持其竞争优势，市场有望进一步发展。就竞争基准而言，NSCLC 市场的特点是老牌製药巨头和新兴生技公司之间的激烈竞争。监管的影响至关重要，严格的核准流程影响新产品上市的速度。北美和欧洲在主导领域处于领先地位，制定了高标准的安全性和有效性要求。儘管这些地区保持着市场份额的主导地位，但由于医疗基础设施投资的增加和患者群体的不断扩大，亚太地区正在崛起成为关键参与者。竞争格局进一步受到策略联盟和併购的影响，随着公司寻求加强市场地位和扩大产品系列，这些联盟和併购变得越来越普遍。

主要趋势和驱动因素：

在标靶治疗和免疫疗法的推动下，非小细胞肺癌 (NSCLC) 市场正经历变革性成长。关键趋势包括：开发个人化医疗方法以提高治疗效果和患者预后；人工智慧在诊断中的应用加速了早期检测和精准治疗方案的製定，从而推动了市场扩张；生物标誌物驱动疗法的兴起是另一项关键趋势，它能够实现更加个性化和有效的治疗方法；研发投入的增加正在刺激创新并创造新的治疗选择；NSCLC发病率的不断上升以及人口老化显着推动了对先进治疗方案的需求；此外，监管机构的支持和突破性治疗方法的快速核准流程也促进了其加速进入市场。新兴市场拥有众多机会，这些市场的医疗基础设施正在发展，人们对肺癌的认知也不断提高。专注于策略合作和拓展产品平臺的公司将更有利于掌握这个充满活力的市场环境。

限制与挑战：

非小细胞肺癌（NSCLC）市场面临许多重大限制与挑战。其中一个主要挑战是标靶治疗和免疫疗法的高成本，限制了低收入地区患者的治疗机会。这些先进疗法的价格往往高得令人望而却步，阻碍了其广泛应用，并加剧了医疗保健资源分配不均的现状。此外，NSCLC复杂的遗传背景要求采取个人化治疗方案，使得治疗通讯协定的标准化变得困难。这种复杂性也增加了医疗服务提供者了解最新进展并据此调整治疗方案的负担。另一个挑战是新治疗方法核准中存在的监管障碍，这可能会延迟产品上市并增加研发成本。此外，NSCLC治疗的副作用可能严重，影响患者的生活品质和治疗顺从性。最后，某些地区全面基因组检测的匮乏阻碍了精准医疗的有效实施，并限制了最佳治疗效果的实现。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

  • 宏观经济分析
  • 市场趋势
  • 市场驱动因素
  • 市场机会
  • 市场限制
  • 复合年均成长率：成长分析
  • 影响分析
  • 新兴市场
  • 技术蓝图
  • 战略框架

第四章 细分市场分析

  • 市场规模及预测：依类型
    • 腺癌
    • 鳞状细胞癌
    • 大细胞癌
  • 市场规模及预测：依产品划分
    • 标靶治疗药物
    • 免疫疗法
    • 化疗药物
    • 放射治疗
  • 市场规模及预测：依技术划分
    • 生物标记检测
    • 基因检测
    • 诊断影像技术
    • 奈米科技
  • 市场规模及预测：依应用领域划分
    • 一线治疗
    • 二级治疗
    • 维持治疗
    • 辅助性治疗
    • 新辅助辅助性治疗
  • 市场规模及预测：依最终用户划分
    • 医院
    • 癌症研究所
    • 专科诊所
    • 製药公司
  • 市场规模及预测：依疾病阶段划分
    • 第一阶段
    • 第二阶段
    • 第三阶段
    • 第四阶段
  • 市场规模及预测：依设备划分
    • 切片检查装置
    • 诊断影像系统
    • 放射治疗设备
  • 市场规模及预测：按解决方案划分
    • 病患管理
    • 临床试验
    • 药物研发
  • 市场规模及预测：依製程划分
    • 药物发现
    • 临床开发
    • 监管部门核准
    • 商业化

第五章 区域分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地区
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲
    • 台湾
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他欧洲地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 撒哈拉以南非洲
    • 其他中东和非洲地区

第六章 市场策略

  • 需求与供给差距分析
  • 贸易和物流限制
  • 价格、成本和利润率趋势
  • 市场渗透率
  • 消费者分析
  • 法规概述

第七章 竞争讯息

  • 市场定位
  • 市场占有率
  • 竞争基准
  • 主要企业的策略

第八章：公司简介

  • BeiGene
  • Innovent Biologics
  • Zai Lab
  • Hutchmed
  • Array BioPharma
  • Blueprint Medicines
  • Mirati Therapeutics
  • Turning Point Therapeutics
  • Iovance Biotherapeutics
  • MacroGenics
  • Daiichi Sankyo
  • Eisai
  • Sumitomo Dainippon Pharma
  • Chugai Pharmaceutical
  • Kyowa Kirin

第九章：关于我们

简介目录
Product Code: GIS34093

Non-Small Cell Lung Cancer (NSCLC) Market is anticipated to expand from $19.5 billion in 2024 to $61.6 billion by 2034, growing at a CAGR of approximately 12.2%. The Non-Small Cell Lung Cancer (NSCLC) Market encompasses the development, production, and distribution of therapeutic solutions targeting NSCLC, the most prevalent form of lung cancer. This market is characterized by innovative treatments, including targeted therapies and immunotherapies, aimed at improving patient outcomes. Driven by rising incidence rates and advancements in precision medicine, the market is poised for growth, with significant investment in research and clinical trials. Key trends include personalized medicine approaches, combination therapies, and the integration of biomarkers for enhanced treatment efficacy.

The Non-Small Cell Lung Cancer (NSCLC) Market is experiencing robust growth, primarily driven by advancements in targeted therapies and immunotherapies. The targeted therapy segment is currently the top-performing, with EGFR inhibitors and ALK inhibitors leading due to their efficacy in specific genetic mutations. Immunotherapy, particularly PD-1 and PD-L1 inhibitors, is the second highest-performing segment, reflecting its increasing adoption as a first-line treatment. Combination therapies are gaining momentum, offering enhanced efficacy and improved patient outcomes. The chemotherapy segment, while declining, remains relevant, especially in combination with other modalities. Personalized medicine is emerging as a key trend, supported by advancements in genomic profiling and biomarker identification. This trend is driving innovation and investment in companion diagnostics. The market is also witnessing a shift towards outpatient settings, influenced by patient preference and cost efficiency. Continuous research and development efforts are expected to yield novel treatment options, further propelling market growth.

Market Segmentation
TypeAdenocarcinoma, Squamous Cell Carcinoma, Large Cell Carcinoma
ProductTargeted Therapy Drugs, Immunotherapy Drugs, Chemotherapy Drugs, Radiotherapy
TechnologyBiomarker Testing, Genetic Testing, Imaging Technologies, Nanotechnology
ApplicationFirst-Line Treatment, Second-Line Treatment, Maintenance Therapy, Adjuvant Therapy, Neoadjuvant Therapy
End UserHospitals, Cancer Research Institutes, Specialty Clinics, Pharmaceutical Companies
StageStage I, Stage II, Stage III, Stage IV
DeviceBiopsy Devices, Diagnostic Imaging Systems, Radiotherapy Equipment
SolutionsPatient Management, Clinical Trials, Drug Development
ProcessDrug Discovery, Clinical Development, Regulatory Approval, Commercialization

Market Snapshot:

The Non-Small Cell Lung Cancer (NSCLC) market is witnessing dynamic changes, with significant shifts in market share driven by innovative pricing strategies and the introduction of new therapeutic products. The landscape is characterized by the launch of novel treatments that aim to address unmet medical needs, thereby enhancing patient outcomes. The competitive pricing of these new entrants is reshaping the market dynamics, encouraging broader accessibility and adoption. Key regions are experiencing varied pricing trends, influenced by local regulatory frameworks and healthcare policies. The market is poised for further evolution as pharmaceutical companies continue to focus on research and development to maintain a competitive edge. In terms of competition benchmarking, the NSCLC market is marked by intense rivalry among established pharmaceutical giants and emerging biotech firms. Regulatory influences play a pivotal role, with stringent approval processes impacting the pace of new product introductions. North America and Europe dominate the regulatory landscape, setting high standards for safety and efficacy. These regions also lead in terms of market share, yet Asia-Pacific is emerging as a significant player due to increased investment in healthcare infrastructure and a growing patient population. The competitive landscape is further shaped by strategic alliances and mergers, which are becoming increasingly common as companies seek to enhance their market position and expand their product portfolios.

Geographical Overview:

The NSCLC market is witnessing robust growth across diverse regions, each exhibiting unique characteristics. North America remains a dominant force, driven by advanced healthcare infrastructure and significant R&D investments. The region's focus on innovative therapies and precision medicine is fostering market expansion. Europe follows closely, with strong governmental support and a rising prevalence of lung cancer contributing to market dynamics. The Asia Pacific region is experiencing rapid growth, propelled by increased healthcare spending and a burgeoning population. Countries like China and India are emerging as key players, with large patient pools and improving healthcare access. Latin America and the Middle East & Africa are also showing promising growth, albeit at a slower pace. In Latin America, Brazil and Mexico are leading the charge with enhanced healthcare initiatives. The Middle East & Africa are recognizing the need for improved cancer care, spurring investments in healthcare infrastructure and treatment options.

Key Trends and Drivers:

The Non-Small Cell Lung Cancer (NSCLC) market is experiencing transformative growth driven by advancements in targeted therapies and immunotherapies. Key trends include the development of personalized medicine approaches, enhancing treatment efficacy and patient outcomes. The integration of artificial intelligence in diagnostics is accelerating early detection and precision treatment planning, boosting market expansion. The rise of biomarker-driven therapies is another pivotal trend, allowing for more tailored and effective treatment regimens. Increasing investment in research and development is fostering innovation, leading to novel therapeutic options. The growing prevalence of NSCLC, coupled with an aging population, is significantly driving demand for advanced treatment solutions. Moreover, regulatory support and expedited approval processes for breakthrough therapies are facilitating faster market entry. Opportunities abound in emerging markets where healthcare infrastructure is improving, and awareness of lung cancer is rising. Companies focusing on strategic collaborations and expanding their product pipelines are well-positioned to capitalize on these dynamic market conditions.

Restraints and Challenges:

The NSCLC market encounters several significant restraints and challenges. One primary challenge is the high cost of targeted therapies and immunotherapies, which limits access for patients in low-income regions. These advanced treatments often come with prohibitive pricing, deterring widespread adoption and exacerbating healthcare inequalities. Moreover, the complexity of NSCLC's genetic landscape necessitates personalized treatment approaches, complicating the standardization of care protocols. This complexity also increases the burden on healthcare providers to stay updated with the latest developments and tailor treatments accordingly. Another challenge is the regulatory hurdles associated with the approval of new therapies, which can delay market entry and increase development costs. Additionally, the side effects associated with NSCLC treatments can be severe, impacting patient quality of life and adherence to therapy. Finally, the limited availability of comprehensive genomic testing in certain regions hampers the ability to implement precision medicine effectively, constraining optimal treatment outcomes.

Key Players:

BeiGene, Innovent Biologics, Zai Lab, Hutchmed, Array BioPharma, Blueprint Medicines, Mirati Therapeutics, Turning Point Therapeutics, Iovance Biotherapeutics, MacroGenics, Daiichi Sankyo, Eisai, Sumitomo Dainippon Pharma, Chugai Pharmaceutical, Kyowa Kirin

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Technology
  • 2.4 Key Market Highlights by Application
  • 2.5 Key Market Highlights by End User
  • 2.6 Key Market Highlights by Stage
  • 2.7 Key Market Highlights by Device
  • 2.8 Key Market Highlights by Solutions
  • 2.9 Key Market Highlights by Process

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Adenocarcinoma
    • 4.1.2 Squamous Cell Carcinoma
    • 4.1.3 Large Cell Carcinoma
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Targeted Therapy Drugs
    • 4.2.2 Immunotherapy Drugs
    • 4.2.3 Chemotherapy Drugs
    • 4.2.4 Radiotherapy
  • 4.3 Market Size & Forecast by Technology (2020-2035)
    • 4.3.1 Biomarker Testing
    • 4.3.2 Genetic Testing
    • 4.3.3 Imaging Technologies
    • 4.3.4 Nanotechnology
  • 4.4 Market Size & Forecast by Application (2020-2035)
    • 4.4.1 First-Line Treatment
    • 4.4.2 Second-Line Treatment
    • 4.4.3 Maintenance Therapy
    • 4.4.4 Adjuvant Therapy
    • 4.4.5 Neoadjuvant Therapy
  • 4.5 Market Size & Forecast by End User (2020-2035)
    • 4.5.1 Hospitals
    • 4.5.2 Cancer Research Institutes
    • 4.5.3 Specialty Clinics
    • 4.5.4 Pharmaceutical Companies
  • 4.6 Market Size & Forecast by Stage (2020-2035)
    • 4.6.1 Stage I
    • 4.6.2 Stage II
    • 4.6.3 Stage III
    • 4.6.4 Stage IV
  • 4.7 Market Size & Forecast by Device (2020-2035)
    • 4.7.1 Biopsy Devices
    • 4.7.2 Diagnostic Imaging Systems
    • 4.7.3 Radiotherapy Equipment
  • 4.8 Market Size & Forecast by Solutions (2020-2035)
    • 4.8.1 Patient Management
    • 4.8.2 Clinical Trials
    • 4.8.3 Drug Development
  • 4.9 Market Size & Forecast by Process (2020-2035)
    • 4.9.1 Drug Discovery
    • 4.9.2 Clinical Development
    • 4.9.3 Regulatory Approval
    • 4.9.4 Commercialization

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Technology
      • 5.2.1.4 Application
      • 5.2.1.5 End User
      • 5.2.1.6 Stage
      • 5.2.1.7 Device
      • 5.2.1.8 Solutions
      • 5.2.1.9 Process
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Technology
      • 5.2.2.4 Application
      • 5.2.2.5 End User
      • 5.2.2.6 Stage
      • 5.2.2.7 Device
      • 5.2.2.8 Solutions
      • 5.2.2.9 Process
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Technology
      • 5.2.3.4 Application
      • 5.2.3.5 End User
      • 5.2.3.6 Stage
      • 5.2.3.7 Device
      • 5.2.3.8 Solutions
      • 5.2.3.9 Process
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Technology
      • 5.3.1.4 Application
      • 5.3.1.5 End User
      • 5.3.1.6 Stage
      • 5.3.1.7 Device
      • 5.3.1.8 Solutions
      • 5.3.1.9 Process
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Technology
      • 5.3.2.4 Application
      • 5.3.2.5 End User
      • 5.3.2.6 Stage
      • 5.3.2.7 Device
      • 5.3.2.8 Solutions
      • 5.3.2.9 Process
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Technology
      • 5.3.3.4 Application
      • 5.3.3.5 End User
      • 5.3.3.6 Stage
      • 5.3.3.7 Device
      • 5.3.3.8 Solutions
      • 5.3.3.9 Process
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Technology
      • 5.4.1.4 Application
      • 5.4.1.5 End User
      • 5.4.1.6 Stage
      • 5.4.1.7 Device
      • 5.4.1.8 Solutions
      • 5.4.1.9 Process
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Technology
      • 5.4.2.4 Application
      • 5.4.2.5 End User
      • 5.4.2.6 Stage
      • 5.4.2.7 Device
      • 5.4.2.8 Solutions
      • 5.4.2.9 Process
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Technology
      • 5.4.3.4 Application
      • 5.4.3.5 End User
      • 5.4.3.6 Stage
      • 5.4.3.7 Device
      • 5.4.3.8 Solutions
      • 5.4.3.9 Process
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Technology
      • 5.4.4.4 Application
      • 5.4.4.5 End User
      • 5.4.4.6 Stage
      • 5.4.4.7 Device
      • 5.4.4.8 Solutions
      • 5.4.4.9 Process
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Technology
      • 5.4.5.4 Application
      • 5.4.5.5 End User
      • 5.4.5.6 Stage
      • 5.4.5.7 Device
      • 5.4.5.8 Solutions
      • 5.4.5.9 Process
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Technology
      • 5.4.6.4 Application
      • 5.4.6.5 End User
      • 5.4.6.6 Stage
      • 5.4.6.7 Device
      • 5.4.6.8 Solutions
      • 5.4.6.9 Process
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Technology
      • 5.4.7.4 Application
      • 5.4.7.5 End User
      • 5.4.7.6 Stage
      • 5.4.7.7 Device
      • 5.4.7.8 Solutions
      • 5.4.7.9 Process
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Technology
      • 5.5.1.4 Application
      • 5.5.1.5 End User
      • 5.5.1.6 Stage
      • 5.5.1.7 Device
      • 5.5.1.8 Solutions
      • 5.5.1.9 Process
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Technology
      • 5.5.2.4 Application
      • 5.5.2.5 End User
      • 5.5.2.6 Stage
      • 5.5.2.7 Device
      • 5.5.2.8 Solutions
      • 5.5.2.9 Process
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Technology
      • 5.5.3.4 Application
      • 5.5.3.5 End User
      • 5.5.3.6 Stage
      • 5.5.3.7 Device
      • 5.5.3.8 Solutions
      • 5.5.3.9 Process
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Technology
      • 5.5.4.4 Application
      • 5.5.4.5 End User
      • 5.5.4.6 Stage
      • 5.5.4.7 Device
      • 5.5.4.8 Solutions
      • 5.5.4.9 Process
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Technology
      • 5.5.5.4 Application
      • 5.5.5.5 End User
      • 5.5.5.6 Stage
      • 5.5.5.7 Device
      • 5.5.5.8 Solutions
      • 5.5.5.9 Process
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Technology
      • 5.5.6.4 Application
      • 5.5.6.5 End User
      • 5.5.6.6 Stage
      • 5.5.6.7 Device
      • 5.5.6.8 Solutions
      • 5.5.6.9 Process
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Technology
      • 5.6.1.4 Application
      • 5.6.1.5 End User
      • 5.6.1.6 Stage
      • 5.6.1.7 Device
      • 5.6.1.8 Solutions
      • 5.6.1.9 Process
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Technology
      • 5.6.2.4 Application
      • 5.6.2.5 End User
      • 5.6.2.6 Stage
      • 5.6.2.7 Device
      • 5.6.2.8 Solutions
      • 5.6.2.9 Process
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Technology
      • 5.6.3.4 Application
      • 5.6.3.5 End User
      • 5.6.3.6 Stage
      • 5.6.3.7 Device
      • 5.6.3.8 Solutions
      • 5.6.3.9 Process
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Technology
      • 5.6.4.4 Application
      • 5.6.4.5 End User
      • 5.6.4.6 Stage
      • 5.6.4.7 Device
      • 5.6.4.8 Solutions
      • 5.6.4.9 Process
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Technology
      • 5.6.5.4 Application
      • 5.6.5.5 End User
      • 5.6.5.6 Stage
      • 5.6.5.7 Device
      • 5.6.5.8 Solutions
      • 5.6.5.9 Process

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 BeiGene
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Innovent Biologics
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Zai Lab
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Hutchmed
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Array BioPharma
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Blueprint Medicines
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Mirati Therapeutics
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Turning Point Therapeutics
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Iovance Biotherapeutics
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 MacroGenics
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Daiichi Sankyo
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Eisai
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Sumitomo Dainippon Pharma
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Chugai Pharmaceutical
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Kyowa Kirin
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us